Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies

March 21st 2024

Side effect profiles driven by fruquintinib use are discussed.

Testing for MRD in Colorectal Cancer

March 18th 2024

Focusing on the adjuvant setting, the expert panel discusses the timing and frequency of MRD testing in patients with colorectal cancer.

MRD Testing Platforms in Colorectal Cancer

March 18th 2024

Colorectal cancer specialists discuss MRD testing platforms and how to choose among the available testing assays.

QOL Remains a Key Goal of the Use of Radiation in Rectal Cancer

March 14th 2024

Nina Sanford, MD, discusses how radiation could help improve QOL for patients with rectal cancer and situations when radiation or surgery could be omitted.

Consideration for Fruquintinib Dosing and Titration

March 14th 2024

Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.

Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC

March 14th 2024

Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.

Multitargeted DNA Test Bests Fecal Immunochemical Test With Higher Sensitivity for CRC

March 13th 2024

Higher sensitivity for CRC and advanced precancerous lesions, but lower specificity for advanced neoplasia, was seen with a next-generation stool DNA test vs a fecal immunochemical test.

Q-TWiST Analysis Demonstrates Benefit of Fruquintinib Plus BSC in Pretreated mCRC

March 12th 2024

Sebastien Stintzing, MD, discusses a Q-TWiST analysis for fruquintinib vs placebo in pretreated metastatic colorectal cancer.

TNO155 Plus Spartalizumab or Ribociclib Elicits Disease Control, Is Safe in Advanced Solid Tumors

March 12th 2024

TNO155 plus spartalizumab or ribociclib was well tolerated and demonstrated disease control in patients with advanced solid tumors.

When is MRD Testing Performed in Colorectal Cancer Treatment?

March 11th 2024

Experts on colorectal cancer discuss the timing of testing for minimal residual disease in the treatment journey.

Treating Colorectal Cancer: Overview of MRD Testing and ctDNA

March 11th 2024

A panel medical oncologists provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.

ABSK061 Demonstrates Safety, Preliminary Efficacy in FGFR2/3+ Advanced Solid Tumors

March 7th 2024

ABSK061 was well tolerated and elicited responses in patients with advanced solid tumors harboring FGFR2/3 alterations.

Dose Modifications and Tolerability Associated with mCRC Treatment Regimens

March 7th 2024

Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.

FRESCO-2 Study Highlights

March 7th 2024

Medical experts provide key takeaways and impacts from the FRESCO-2 study.

Immunotherapy Success Signals Paradigm Shift Toward Nonoperative Management in Select GI Cancers

March 4th 2024

Michael J. Overman, MD, discusses the potential advantages of using nonoperative immunotherapy-based approaches in select gastrointestinal cancers.

A2B530 Receives FDA Orphan Drug Designation in CRC

March 4th 2024

The FDA has granted orphan drug designation to A2B530 for the treatment of select patients with colorectal cancer.

Dr Pedersen on Updates in mCRC Management

March 1st 2024

Katrina S. Pedersen, MD, MS, discusses key updates and FDA approvals from 2023 in metastatic colorectal cancer.

Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment

February 29th 2024

Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.

Fruquintinib MoA and Toxicity Profile Overview

February 29th 2024

Key safety considerations for the use of fruquintinib are explored.

Discordant dMMR/IHC Status Correlates With Improved Treatment Outcomes in CRC and Endometrial Cancer

February 27th 2024

Patients with mismatch repair–deficient, immunohistochemistry-intact colorectal cancer or endometrial cancer benefit from immune checkpoint inhibitors.